

## This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Hematology</b>				
Sickle cell disease	Adenosine A <sub>2A</sub> receptor (ADORA <sub>2A</sub> )	<p>Studies in mice suggest that ADORA<sub>2A</sub> agonists could help treat sickle cell disease. In a mouse model of sickle cell disease, the selective ADORA<sub>2A</sub> agonist apadenoson decreased inflammatory cell accumulation in the lung and improved breathing compared with a vehicle control. Next steps include testing the safety of another ADORA<sub>2A</sub> agonist, regadenoson, in patients with sickle cell disease.</p> <p>Lexiscan regadenoson, a selective ADORA<sub>2A</sub> agonist, is marketed by Gilead Sciences Inc. and Astellas Pharma Inc. as a pharmaceutical stress agent for cardiovascular diagnostic imaging.</p> <p>Stedivaze apadenoson, a selective ADORA<sub>2A</sub> agonist from Clinical Data Inc., is in Phase III testing as a pharmaceutical stress agent for cardiovascular diagnostic imaging.</p> <p><b>SciBX 3(37); doi:10.1038/scibx.2010.1120</b> Published online Sept. 23, 2010</p>	Unpatented; unavailable for licensing	<p>Wallace, K.L. &amp; Linden, J. <i>et al. Blood</i>; published online Aug. 26, 2010; doi:10.1182/blood-2010-06-290643</p> <p><b>Contact:</b> Joel Linden, La Jolla Institute for Allergy and Immunology, La Jolla, Calif. e-mail: <a href="mailto:jlinden@liai.org">jlinden@liai.org</a></p>